0000000000148941

AUTHOR

D'auria G.

showing 2 related works from this author

Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020

2020

8 páginas, 3 figuras

Infecções Respiratórias0301 basic medicineMESH: Coronavirus InfectionsEpidemiology[SDV]Life Sciences [q-bio]Distribution (economics)WastewaterMESH: Base SequenceSevere Acute Respiratory SyndromeMESH: World Health OrganizationPandemicMESH: CoronavirusMESH: COVID-19SequencingViralCladeNomenclatureGenomebiologyNomenclatureCOVID-19; Europe; NGS; SARS-CoV-2; WGS; nomenclature; sequencing; Base Sequence; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Europe; Genome Viral; Humans; Phylogeography; Pneumonia Viral; RNA Viral; RNA-Dependent RNA Polymerase; SARS-CoV-2; Severe Acute Respiratory Syndrome; Spatio-Temporal Analysis; World Health Organization; PandemicsC500sequencingEuropean region3. Good healthEuropePhylogeographyGeographyMESH: PhylogeographyMESH: RNA-Dependent RNA PolymeraseMESH: RNA ViralNGSMESH: BetacoronavirusRNA ViralSpatio-Temporal AnalysinomenclatureMESH: Genome ViralCoronavirus InfectionsCartographyHumanBioquímicaMESH: PandemicsSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)CoronaviruPneumonia Viral030106 microbiologyGenome ViralWorld Health OrganizationCOVID-19 ; Europe ; NGS ; SARS-CoV-2 ; WGS ; nomenclature ; sequencing03 medical and health sciencesBetacoronavirusMESH: Spatio-Temporal AnalysisSpatio-Temporal AnalysisMESH: Severe Acute Respiratory SyndromeVirologyHumansMESH: SARS-CoV-2PandemicsWhole genome sequencingMESH: HumansWhole Genome SequencingBetacoronaviruBase SequenceCoronavirus Infectionbusiness.industrySARS-CoV-2Public Health Environmental and Occupational HealthCOVID-19Pneumoniabiology.organism_classificationRNA-Dependent RNA PolymeraseB900Coronavirus030104 developmental biologyMESH: Pneumonia ViralRNASARS_CoV-23111 BiomedicineMESH: EuropeHuman medicinebusinessBetacoronavirusWGSEurosurveillance
researchProduct

Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a m…

2023

BackgroundIn triple negative breast cancer patients treated with neoadjuvant chemotherapy, residual disease at surgery is the most relevant unfavorable prognostic factor. Current guidelines consider the use of adjuvant capecitabine, based on the results of the randomized CREATE-X study, carried out in Asian patients and including a small subset of triple negative tumors. Thus far, evidence on Caucasian patients is limited, and no real-world data are available.MethodsWe carried out a multicenter, observational study, involving 44 oncologic centres. Triple negative breast cancer patients with residual disease, treated with adjuvant capecitabine from January 2017 through June 2021, were recrui…

neoadjuvant treatmentCancer ResearchOncologytriple negative breast canceradjuvant capecitabineresidual tumorsresidual tumortreatment discontinuationFrontiers in Oncology
researchProduct